Feasibility and Safety of Hydrogen Gas Inhalation for Post-Cardiac Arrest Syndrome – First-in-Human Pilot Study.
This human publication evaluated hydrogen gas in 2014 patients with out-of-hospital cardiac arrest achieved spontaneous return of circulation. This pilot study suggests therapeutic potential, while larger randomized, placebo-controlled studies are needed to confirm the finding.
Read MoreHydrogen Gas Inhalation Treatment in Acute Cerebral Infarction: A Randomized Controlled Clinical Study on Safety and Neuroprotection.
In 50 patients with a therapeutic time window of 6 to 24 hours, the H₂ group showed no significant adverse effects with improvements in oxygen saturation. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
Read MoreEffectiveness and safety of hydrogen inhalation therapy as an additional treatment for hypertension in real-world practice: a retrospective, observational study in China.
Hydrogen inhalation was associated with greater reductions in systolic and diastolic blood pressure than control treatment through 24 weeks.
Read MoreEffectiveness and safety of hydrogen inhalation as an adjunct treatment in Chinese type 2 diabetes patients: A retrospective, observational, double-arm, real-life clinical study.
In 2 patients, compared to the control group, participants in HI group maintained greater improvement in the level of HbA1c (-0.94% vs -0.46%), FPG (-22.7 mg/dL vs -11.7 mg/dL), total cholesterol (-12.9 mg/dL vs -4.4 mg/dL), HOMA-IR (-0.76 vs -0.17) and HOMA-β (8.2% vs 1.98%) with all p 1% reduction at the follow-up period was higher in the HI group. Patients in the control group were more likely to attain HbA1c ≥ 9%. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence glucose regulation and metabolic health.
Read MoreReal-World Effectiveness and Safety of Hydrogen Inhalation in Chinese Patients with Type 2 Diabetes: A Single-Arm, Retrospective Study.
In 431 patients, higher baseline HbA1c level and shorter diabetes duration is related to greater clinical response to HI. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence glucose regulation and metabolic health.
Read MoreThe effect of a low dose hydrogen-oxygen mixture inhalation in midlife/older adults with hypertension: A randomized, placebo-controlled trial.
In 60 participants with hypertension aged 50-70 years, when stratified by age (aged 50-59 years versus aged 60-70 years), participants in the older H₂-O₂ group showed a larger reduction in right arm SBP compared with that in the younger group (p < 0.05). These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence blood-pressure regulation.
Read MoreThe effect of hydrogen-rich water interventions on lipid profiles in adults with overweight or obesity and associated metabolic disorders: a systematic review and meta-analysis of randomized controlled trials.
In 2025 participants with placebo or standard water in adults with mean body mass index (BMI) ≥ 25 kg/m2, HRW significantly reduced total cholesterol (TC) (WMD: − 6.71 mg/dL; 95% CI: − 10.38 to − 3.04; P < 0.001) and low-density lipoprotein cholesterol (LDL-C) (WMD: − 3.21 mg/dL; 95% CI: − 6.31 to − 0.10; P = 0.043). These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
Read MoreHydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled trial.
In participants with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), there was a significant reduction of Cough Assessment Test score in Hydrogen/oxygen group compared to control (- 11.00 vs. - 6.00, p < 0.001). These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
Read MorePreliminary Effects of Hydrogen-Oxygen Inhalation on Nodule Size, IL-6, and Neutrophils in Patients with Small Pulmonary Nodules.
In the smoking subgroup, IL-6 level and neutrophil count also decreased significantly after hydrogen-oxygen inhalation, while CRP remained relatively stable.
Read MoreThe Benefit of Hydrogen Gas as an Adjunctive Therapy for Chronic Obstructive Pulmonary Disease.
In 6 patients, however, no significant differences were observed in lung function, DLCO, sleep quality, and 6 MWT before and after hydrogen therapy. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
Read MoreProtective effects of hydrogen gas against sepsis-induced acute lung injury via regulation of mitochondrial function and dynamics.
In By using cecal ligation and puncture (CLP), a classic septic model, the researchers explored the role of 2% H₂ treatment in sepsis-induced acute lung injury (ALI) linked to mitochondrial function and, therapy with 2% H₂ increased PaO2/FiO2 ratios, MMP and ATP levels, RCR, complex I activity and MFN2 expression but decreased histological score and Drp1 levels in the presence of sepsis. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
Read MoreCan Hydrogen Water Enhance Oxygen Saturation in Patients with Chronic Lung Disease? A Non-Randomized, Observational Pilot Study.
In 10 patients with chronic lung diseases due to COPD (n = 7), HRW administration was associated with a significant increase in oxygen saturation (SpO2) and decrease in TBARS, MDA, and diene conjugates, with an increase in vitamin E and nitrite levels, compared to baseline levels. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence oxidative-stress regulation.
Read MoreRandomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study.
In 20 participants, this pilot study revealed that the inhalation of molecular hydrogen gas was safe, but did not show any beneficial effects in patients with PD. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
Read MoreInhalation of hydrogen gas elevates urinary 8-hydroxy-2′-deoxyguanine in Parkinson’s disease.
In 20 patients with an 8-week washout period in 20 patients with PD, although the researchers did not observe any beneficial effect of hydrogen in the authors' short trial, the researchers propose that the increased 8-OHdG and other reported stress responses from hydrogen may indicate that its beneficial effects are partly or largely mediated by hormetic mechanisms. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
Read MoreEffects of concomitant use of hydrogen water and photobiomodulation on Parkinson disease: A pilot study.
In 18 patients with PD (age 30-80 years), this novel, proof-of-concept study demonstrated that PBM+H₂ therapy is safe and reduces disease severity. This small, pilot study suggests therapeutic potential, while larger randomized, placebo-controlled studies are needed to confirm the finding.
Read MoreBlog Categories
Recent Posts
October 21, 2020
November 16, 2020
October 02, 2017